Agenus (AGEN) Research & Development (2010 - 2026)
Agenus (AGEN) posted quarterly Research & Development of $11.8 million for Q1 2026, down 45.07% year-over-year from $21.5 million in Q1 2025, and up 57.4% quarter-over-quarter from $7.5 million in Q4 2025.
Agenus (AGEN) Research & Development (2010 - 2026) Analysis & Trends
Agenus' Research & Development history runs 17 years deep, the most recent figure standing at $11.8 million for Q1 2026.
- In Q1 2026, Research & Development fell 45.07% year-over-year to $11.8 million; the TTM figure through Mar 2026 stood at $69.6 million (down 47.69% YoY), while the FY2025 annual figure was $79.3 million, down 48.99% from the prior year.
- Research & Development for Q1 2026 stood at $11.8 million, up from $7.5 million in the prior quarter.
- The five-year high for Research & Development was $66.7 million in Q4 2023, with the low at $7.5 million in Q4 2025.
- The 5-year median for Research & Development is $42.4 million (2022), against an average of $39.3 million.
- The sharpest annual moves came in 2023 and 2025: Research & Development soared 34.58% in 2023, then slumped 77.76% in 2025.
- Agenus' Research & Development stood at $53.3 million in 2022, then rose by 25.23% to $66.7 million in 2023, then slumped by 49.38% to $33.8 million in 2024, then slumped by 77.76% to $7.5 million in 2025, then soared by 57.4% to $11.8 million in 2026.
- Business Quant data shows AGEN's Research & Development at $11.8 million in Q1 2026, $7.5 million in Q4 2025, and $23.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Agenus | 311.95 Mn | 286.43 Mn | 34.52 Mn | 14.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 14.76 Mn |
| Mar 31, 2026 | 11.82 Mn |
| Dec 31, 2025 | 7.51 Mn |
| Sep 30, 2025 | 23.60 Mn |
| Jun 30, 2025 | 26.71 Mn |
| Mar 31, 2025 | 21.52 Mn |
| Dec 31, 2024 | 33.78 Mn |
| Sep 30, 2024 | 41.06 Mn |
| Jun 30, 2024 | 36.77 Mn |
| Mar 31, 2024 | 43.93 Mn |
| Dec 31, 2023 | 66.72 Mn |
| Sep 30, 2023 | 51.44 Mn |
| Jun 30, 2023 | 59.29 Mn |
| Mar 31, 2023 | 57.12 Mn |
| Dec 31, 2022 | 53.28 Mn |
| Sep 30, 2022 | 46.01 Mn |
| Jun 30, 2022 | 44.96 Mn |
| Mar 31, 2022 | 42.44 Mn |
| Dec 31, 2021 | 53.49 Mn |
| Sep 30, 2021 | 42.94 Mn |